Necrotizing Fasciitis clinical trials at UC Health
1 research study open to eligible people
Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections
open to eligible people ages 12 years and up
The purpose of this study is to determine whether AB103 is safe and effective in the treatment of patients with necrotizing soft tissue infections receiving standard of care therapy.
at UCLA UC Irvine UC Davis UCSD